-
公开(公告)号：US10351536B2
公开(公告)日：2019-07-16
申请号：US15038470
申请日：2014-11-20
发明人： Minhua Chen , Yanfeng Zhang , Chaohui Yang , Xiaoyu Zhang , Peng Wang , Pixu Li
IPC分类号： C07D249/12
摘要： Novel crystalline forms of lesinurad and its sodium salt, processes for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transporter 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.
-
公开(公告)号：US09969701B2
公开(公告)日：2018-05-15
申请号：US15106361
申请日：2014-12-19
发明人： Minhua Chen , Yanfeng Zhang , Chaohui Yang , Xiaoyu Zhang , Peng Wang , Pixu Li
IPC分类号： C07D249/12 , C07C59/06 , C07D207/16
CPC分类号： C07D249/12 , C07B2200/13 , C07C59/06 , C07D207/16
摘要： Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.
-
公开(公告)号：US09957240B2
公开(公告)日：2018-05-01
申请号：US15528153
申请日：2015-12-08
发明人： Minhua Chen , Yanfeng Zhang , Chaohui Yang , Xiaoyu Zhang , Jiaoyang Li , Peng Wang , Pixu Li
IPC分类号： C07D257/04
CPC分类号： C07D257/04 , A61K31/225 , A61K31/41 , C07B2200/13 , C07C233/47 , A61K2300/00
摘要： Novel crystalline Forms of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyl carbamoyl) propionate-(S)-3′-methyl-T-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hydrate, methods for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition, such as heart failure, are disclosed.
-
公开(公告)号：US12091414B2
公开(公告)日：2024-09-17
申请号：US17427357
申请日：2020-05-08
IPC分类号： C07D487/14
CPC分类号： C07D487/14 , C07B2200/13
摘要： The present application provides a upadacitinib salt compound and a preparation method therefor. The salt involved in the method in the present application has an easy preparation operation, a cheap raw material easy to get, and a good purification effect on upadacitinib, and is beneficial to industrial production.
-
公开(公告)号：US11673862B2
公开(公告)日：2023-06-13
申请号：US16256596
申请日：2019-01-24
发明人： Peng Wang , Pixu Li , Qiang Wei , Yuanhua Liu
IPC分类号： C07D207/27 , A61K31/4015 , C07C53/19 , C07C53/50 , C07C67/307 , C07C69/63 , C07C71/00 , C07C209/08 , C07C231/14 , C07C233/05 , C07C237/06
CPC分类号： C07D207/27 , A61K31/4015 , C07C53/19 , C07C53/50 , C07C67/307 , C07C69/63 , C07C71/00 , C07C209/08 , C07C231/14 , C07C233/05 , C07C237/06
摘要： The present invention provides a scalable synthesis of enantiomerically pure brivaracetam, and related derivatives.
-
公开(公告)号：US11161851B2
公开(公告)日：2021-11-02
申请号：US16762122
申请日：2018-11-05
发明人： Peng Wang , Pixu Li , Xiangyong Gu , Yadong Ge , Zhong Wang , Feng Gao , Qiangqiang Du
IPC分类号： C07D471/02 , C07D471/04 , C07D487/04 , C07D213/75 , C07D403/12 , C07F5/02
摘要： The present invention relates to a method for preparing the compound of formula IV, compound of formula XI, and acalabrutinib, a new generation of bruton tyrosine kinase (BTK) inhibitor.
-
公开(公告)号：US09751889B2
公开(公告)日：2017-09-05
申请号：US15100247
申请日：2014-11-26
发明人： Minhua Chen , Yanfeng Zhang , Chaohui Yang , Xiaoyu Zhang , Peng Wang , Pixu Li , Fei Lu , Heng Ge
IPC分类号： A01N43/90 , A61K31/519 , C07D487/00 , C07D487/04
CPC分类号： C07D487/04 , A61K31/519 , C07B2200/13
摘要： Crystalline Form I of ibrutinib, processes for its preparation, pharmaceutical compositions comprising the new Form, and use of Form I of ibrutinib for treating or delaying diseases or disorders related to activity of Bruton's tyrosine kinase (BTK) proteins are disclosed. The novel Form was characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. It can be readily prepared and is suitable for use in the preparation of solid dosage forms.
-
公开(公告)号：US11926633B2
公开(公告)日：2024-03-12
申请号：US17272369
申请日：2019-08-26
IPC分类号： C07D487/14 , C07D207/08 , C07D207/16 , C07D241/20 , C07D487/04
CPC分类号： C07D487/14 , C07D207/08 , C07D207/16 , C07D241/20 , C07D487/04
摘要： The present disclosure relates to a JAK inhibitor upadacitinib intermediate and a preparation method therefor, and to a preparation method for a JAK inhibitor upadacitinib. The upadacitinib intermediate of the present application is as shown in Formula (II) or Formula (III),
wherein, R is a protective group of nitrogen atoms, and R1 is an open-chain or cyclic amine group. Compared with the prior art, the method for the synthesis of upadacitinib of the present application, significantly reduces cost, is environmentally-friendly. And the quality of the final product is well controlled.-
公开(公告)号：US11377426B2
公开(公告)日：2022-07-05
申请号：US16770035
申请日：2018-12-03
发明人： Pixu Li , Peng Wang , Xiangyong Gu , Hailong Yang , Zhong Wang , Qianghua Jiang , Yuanhua Liu , Hui Xia
IPC分类号： C07D239/54 , B01J23/44 , B01J25/02
摘要： The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.017 秒)
